{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:48:10Z","timestamp":1787028490436,"version":"build-2736575974"},"reference-count":32,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Polish Ministry of Science and Higher Education","award":["1\/2022"],"award-info":[{"award-number":["1\/2022"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Ceftobiprole is a novel \u03b2-lactam antibiotic, active against methicillin-resistant Staphylococcus aureus, vancomycin-resistant S. aureus and penicillin-resistant Streptococcus pneumoniae. To artificially generate potential degradation products (DPs) of ceftobiprole that may be formed under relevant storage conditions, acidic, alkaline, oxidative, photolytic and thermolytic stress tests were performed in both solution and solid state. A novel selective HPLC method was developed for the separation of ceftobiprole from its DPs and synthesis by-products (SBPs) using Kinetex Biphenyl column, ammonium acetate buffer pH 5.8 and acetonitrile. The kinetic studies demonstrated the low stability of ceftobiprole in alkaline solution, in the presence of an oxidising agent and under irradiation with near UV. In the solid state, ceftobiprole underwent oxidation when the powder was irradiated with visible light and UV. Based on mass spectroscopic analysis, 13 new structural formulas of SBPs and DPs were proposed, along with molecular formulas for three other DPs obtained in solution and four oxidative DPs characteristic of solid-state degradation.<\/jats:p>","DOI":"10.3390\/ijms232315252","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T02:13:12Z","timestamp":1670206392000},"page":"15252","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Study of Degradation Kinetics and Structural Analysis of Related Substances of Ceftobiprole by HPLC with UV and MS\/MS Detection"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1881-7356","authenticated-orcid":false,"given":"Dariusz","family":"Boczar","sequence":"first","affiliation":[{"name":"Department of Synthetic Drugs, National Medicines Institute, Che\u0142mska 30\/34, 00-725 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6544-5412","authenticated-orcid":false,"given":"Katarzyna","family":"Bus","sequence":"additional","affiliation":[{"name":"Department of Spectrometric Methods, National Medicines Institute, Che\u0142mska 30\/34, 00-725 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7329-3081","authenticated-orcid":false,"given":"Katarzyna","family":"Michalska","sequence":"additional","affiliation":[{"name":"Department of Synthetic Drugs, National Medicines Institute, Che\u0142mska 30\/34, 00-725 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,3]]},"reference":[{"key":"ref_1","first-page":"57","article-title":"Ceftobiprole: An Emerging Therapeutic Option for Resistant and Complicated Infections","volume":"3","author":"Reygaert","year":"2011","journal-title":"Clin. Med. Insights Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jpba.2017.07.060","article-title":"Identification and determination of related substances of ceftaroline fosamil in medicinal product by high performance liquid chromatography with diode array detection and tandem mass spectrometry","volume":"145","author":"Karpiuk","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jpba.2019.05.057","article-title":"Structural elucidation of a dimeric impurity in the process development of ceftolozane using LC\/HRMS and 2D-NMR","volume":"174","author":"Liao","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"dlab141","DOI":"10.1093\/jacamr\/dlab141","article-title":"Assessment of ceftolozane\/tazobactam stability in elastomeric devices and suitability for continuous infusion via outpatient parenteral antimicrobial therapy","volume":"3","author":"Jamieson","year":"2021","journal-title":"JAC-Antimicrob. Resist."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/fmb-2019-0332","article-title":"Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: A novel protocol for a double-blind, Phase III trial","volume":"15","author":"Hamed","year":"2020","journal-title":"Future Microbiol."},{"key":"ref_6","unstructured":"Taylor, P. (2022, November 25). Basilea Preps Key US Filing for MRSA Antibiotic Ceftobiprole. Available online: https:\/\/pharmaphorum.com\/news\/basilea-preps-key-us-filing-for-mrsa-antibiotic-ceftobiprole\/."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e1507","DOI":"10.1093\/cid\/ciaa974","article-title":"Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET)","volume":"73","author":"Overcash","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lupia, T., Pallotto, C., Corcione, S., Boglione, L., and De Rosa, F.G. (2021). Ceftobiprole Perspective: Current and Potential Future Indications. Antibiotics, 10.","DOI":"10.3390\/antibiotics10020170"},{"key":"ref_9","unstructured":"(2022, August 11). European Medicines Agency Decision P\/0311\/2020. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/paediatric-investigation-plans\/emea-000205-pip02-11-m04."},{"key":"ref_10","unstructured":"Electronic Medicines Compendium (emc) (2022, November 25). Zevtera 500 mg Powder for Concentrate for Solution for Infusion\u2014Summary of Product Characteristics. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/9164."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00128071-200809040-00004","article-title":"Ceftobiprole. A Review of a Broad-Spectrum and Anti-MRSA Cephalosporin","volume":"9","author":"Zhanel","year":"2008","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1080\/14787210.2019.1667229","article-title":"Ceftobiprole: Drug evaluation and place in therapy","volume":"17","author":"Giacobbe","year":"2019","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_13","unstructured":"International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2022, November 25). ICH Topic Q1A (R2). Stability Testing of New Drug Substances and Products., Available online: https:\/\/database.ich.org\/sites\/default\/files\/Q1A%28R2%29%20Guideline.pdf."},{"key":"ref_14","unstructured":"Baertschi, S.W., Alsante, K.M., and Reed, R.A. (2011). Stress testing: A predictive tool. Pharmaceutical Stress Testing: Predicting Drug Degradation, CRC Press. [2nd ed.]."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Binert-Kusztal, \u017b., Starek, M., \u017bandarek, J., and D\u0105browska, M. (2021). Development of TLC Chromatographic-Densitometric Procedure for Qualitative and Quantitative Analysis of Ceftobiprole. Processes, 9.","DOI":"10.3390\/pr9040708"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Binert-Kusztal, \u017b., \u017bandarek, J., Starek, M., and D\u0105browska, M. (2022). Optimizations of the Conditions for Ceftobiprole Determination in a Complex Matrix. Processes, 10.","DOI":"10.3390\/pr10112196"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e00515-19","DOI":"10.1128\/AAC.00515-19","article-title":"Validation and Application of an HPLC-DAD Method for Routine Therapeutic Drug Monitoring of Ceftobiprole","volume":"63","author":"Lima","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1515\/cclm-2021-0423","article-title":"Simple and accurate quantitative analysis of cefiderocol and ceftobiprole in human plasma using liquid chromatography-isotope dilution tandem mass spectrometry: Interest for their therapeutic drug monitoring and pharmacokinetic studies","volume":"59","author":"Llopis","year":"2021","journal-title":"Clin. Chem. Lab. Med. (CCLM)"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Phillips, A.M.M.M.F. (2020). Therapeutic Potentials of \u03b2-Lactam. Synthetic Approaches to Nonaromatic Nitrogen Heterocycles, John Wiley & Sons Ltd.","DOI":"10.1002\/9781119708841"},{"key":"ref_20","unstructured":"(2022, November 25). Chemicalize. Available online: https:\/\/chemicalize.com\/welcome."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"113783","DOI":"10.1016\/j.jpba.2020.113783","article-title":"The solution and solid-state degradation study followed by identification of tedizolid related compounds in medicinal product by high performance liquid chromatography with diode array and tandem mass spectrometry detection","volume":"194","author":"Michalska","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.1039\/b810384d","article-title":"Oxidation mechanism of dimethyl sulfoxide (DMSO) by OH radical in liquid phase","volume":"10","author":"Baptista","year":"2008","journal-title":"Phys. Chem. Chem. Phys."},{"key":"ref_23","unstructured":"Baertschi, S.W., Alsante, K.M., and Reed, R.A. (2011). Photostability stress testing. Pharmaceutical Stress Testing: Predicting Drug Degradation, CRC Press. [2nd ed.]."},{"key":"ref_24","unstructured":"International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2022, November 25). ICH Topic Q1B. Photostability Testing of New Active Substances and Medicinal Products., Available online: https:\/\/database.ich.org\/sites\/default\/files\/Q1B%20Guideline.pdf."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1021\/acs.oprd.7b00143","article-title":"Patent Review of Manufacturing Routes to Fifth-Generation Cephalosporin Drugs. Part 2, Ceftaroline Fosamil and Ceftobiprole Medocaril","volume":"21","author":"Hughes","year":"2017","journal-title":"Org. Process Res. Dev."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Yang, Y. (2016). Side Reactions in Peptide Synthesis, Academic Press.","DOI":"10.1016\/B978-0-12-801009-9.00014-8"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6544","DOI":"10.1021\/ja00855a043","article-title":"Pyruvamide semicarbazone formation. Kinetics, mechanism, and pertinence to pyruvamide-dependent histidine decarboxylase","volume":"97","author":"Young","year":"1975","journal-title":"J. Am. Chem. Soc."},{"key":"ref_28","unstructured":"Baertschi, S.W., Alsante, K.M., and Reed, R.A. (2011). Stress testing: The chemistry of drug degradation. Pharmaceutical Stress Testing: Predicting Drug Degradation, CRC Press. [2nd ed.]."},{"key":"ref_29","unstructured":"Council of Europe (2022). Cefixime. Ph. Eur. 10.5, 1188 (04\/2018). European Pharmacopoeia, Council of Europe."},{"key":"ref_30","unstructured":"Council of Europe (2022). Cefprozil. Ph Eur. 10.5, 2342 (01\/2017). European Pharmacopoeia, Council of Europe."},{"key":"ref_31","unstructured":"Steven, W., Baertschi, K.M.A., and Robert, A.R. (2011). Oxidative Susceptibility Testing. Pharmaceutical Stress Testing: Predicting Drug Degradation, CRC Press. [2nd ed.]."},{"key":"ref_32","unstructured":"Council of Europe (2022). Cefradine. Ph. Eur. 10.5, 0814 (01\/2014). European Pharmacopoeia, Council of Europe."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/23\/15252\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:33:29Z","timestamp":1760146409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/23\/15252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,3]]},"references-count":32,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["ijms232315252"],"URL":"https:\/\/doi.org\/10.3390\/ijms232315252","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,3]]}}}